Method of using metaloporphyrins for treatment of arteriosclerotic lesions

• US 20040202609A1
• Filed: 04/30/2004
• Published: 10/14/2004
• Est. Priority Date: 06/21/2002
• Status: Active Grant

• Current Assignee: Edwin L. Adair
• Original Assignee: Edwin L. Adair
• Inventors: Adair, Edwin L.
• Granted Patent: US 7,067,276 B2
• Time in Patent Office: Days
• US Class Current: 424/1.11
• CPC Class Codes: A61K 49/0021 the fluorescent group being a small organic molecule
• CPC Class Codes: A61K 49/0036 Porphyrins used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546
• CPC Class Codes: A61K 51/0485 Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for treating arteriosclerotic lesions is provided wherein the method is characterized by administering a chemical compound to the patient, the compound being a porphyrin complexed with a radioactive metal. Cells which exhibit an affinity for the porphyrin element indicate sites of plaque buildup. The radioactive metal within the compound is cytotoxic to cells in and surrounding the plaque and may allow tomographic scanning of the plaque as well. The complexed compound can be introduced to the patient a desired number of times to provide the necessary radiation treatment and ongoing monitoring of plaque removal.

Claims

1. A method of treating arteriosclerotic disease comprising administering a therapeutically effective dose of a cytotoxic compound comprising a porphyrin complexed with a radioactive metal to a mammal.

2. The method of claim 1, wherein the radioactive metal is selected from the group consisting of ⁶⁷Cu, ⁶⁴Cu, ¹³¹I, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ²¹²Bi and ¹²⁵I.

3. The method of claim 1, wherein the radioactive metal is ⁶⁴Cu.

4. The method of claim 1, wherein the radioactive metal is ⁶⁷Cu.

5. The method of claim 1, wherein the prophyrin is selected from the group consisting of protoporphyrin IX, TCPP, hematoporphyrin derivative, photofrin, uroporphyrin, coproporphyrin, TPPS, and TMPP.

6. The method of claim 1, wherein the therapeutically effective dose is between about 5 Gy and about 25 Gy of radiation.

7. The method of claim 1, wherein the therapeutically effective dose is between about 9 Gy and about 18 Gy of radiation.

8. The method of claim 1, further comprising the step of:

conducting tomographic imaging of the mammal after the administering step.

9. The method of claim 8, further comprising the step of:

administering a compound comprising a porphyrin complexed with a radioactive metal to the mammal after the conducting tomographic imaging step;

conducting tomographic imaging of the mammal; and

,

comparing imaging results from tomographic imaging conducted following administration of the cytotoxic compound with imaging results from tomograhic imaging conducted following administration of the compound to assess treatment results.

10. A method, as claimed in claim 8, wherein the tomographic imaging is positron emission tomography.

11. A method, as claimed in claim 8, wherein the tomographic imaging is single photon emission computed tomography.

12. A radiopharmaceutical composition for the treatment of arteriosclerosis comprising a porphyrin complexed with a cytotoxic radiation-emitting metal selected from the group consisting of ⁶⁷Cu, ⁶⁴Cu, ¹³¹I, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ²¹²Bi and ¹²⁵I.

13. The radiopharmaceutical composition of claim 12, wherein the porphyrin is selected from the group consisting of Protoporphyrin IX;

Porphine;

Octaethylporphine;

Hematoporphyrin IX;

Etioporphyrin;

Etioporphyrin I;

meso-Tetraphenylporphine;

Coproporphyrin I;

Coproporphyrin III;

Deuteroporphyrin IX;

Mesoporphyrin IX;

Tetra Tosylate;

Uroporphyrin I; and

Iso-hematoporphyrin IX.